L Edward Clemens
Overview
Explore the profile of L Edward Clemens including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
129
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Woodburn K, Jaynes J, Clemens L
J Fungi (Basel)
. 2020 Sep;
6(3).
PMID: 32971819
Cutaneous invasive fungal wound infections after life-threatening dismounted complex blast injury (DCBI) and natural disasters complicate clinical care. These wounds often require aggressive repeated surgical debridement, can result in amputations...
2.
Woodburn K, Jaynes J, Clemens L
Antibiotics (Basel)
. 2020 Jan;
9(1).
PMID: 31940992
Acne vulgaris, caused by the Gram-positive bacterium , is a prevalent dermatologic condition with substantial cutaneous and psychological morbidity. Mild acne is treated with topical antibiotics with more severe inflammatory...
3.
Woodburn K, Clemens L, Jaynes J, Joubert L, Botha A, Nazik H, et al.
Antimicrob Agents Chemother
. 2019 Aug;
63(11).
PMID: 31451496
Recurrent vulvovaginal candidiasis (RVVC) is a widespread chronic infection that has a substantial negative impact on work and quality of life. The development of antimicrobial resistance and biofilm formation are...
4.
Woodburn K, Jaynes J, Clemens L
Front Microbiol
. 2019 Aug;
10:1688.
PMID: 31396193
The relentless growth of multidrug resistance and generation of recalcitrant biofilm are major obstacles in treating wounds, particularly in austere military environments where broad-spectrum pathogen coverage is needed. Designed antimicrobial...
5.
Clemens L, Jaynes J, Lim E, Kolar S, Reins R, Baidouri H, et al.
Invest Ophthalmol Vis Sci
. 2017 Dec;
58(14):6273-6281.
PMID: 29242901
Purpose: To limit corneal damage and potential loss of vision, bacterial keratitis must be treated aggressively. Innovation in antimicrobials is required due to the need for empirical treatment and the...
6.
Chandalia A, Clarke H, Clemens L, Pandey B, Vicena V, Lee P, et al.
PPAR Res
. 2009 May;
2009:706852.
PMID: 19404482
MBX-102/JNJ-39659100 (MBX-102) is a selective, partial PPAR-γ agonist that lowers glucose in the absence of some of the side effects, such as weight gain and edema, that are observed with...
7.
Gregoire F, Zhang F, Clarke H, Gustafson T, Sears D, Favelyukis S, et al.
Mol Endocrinol
. 2009 Apr;
23(7):975-88.
PMID: 19389808
MBX-102/JNJ39659100 (MBX-102) is in clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. MBX-102 is a nonthiazolidinedione (TZD) selective partial agonist of peroxisome proliferator-activated receptor...
8.
Allen T, Zhang F, Moodie S, Clemens L, Smith A, Gregoire F, et al.
Diabetes
. 2006 Aug;
55(9):2523-33.
PMID: 16936200
Halofenate has been shown previously to lower triglycerides in dyslipidemic subjects. In addition, significant decreases in fasting plasma glucose were observed but only in type 2 diabetic patients. We hypothesized...